Addex Therapeutics Ltd (ADXN)
SIX
Real-time Data
07:00 AM
Day's Range
0.039252 wk Range
0.0336Overview - ADXN - Addex Therapeutics Ltd
Key Statistics
Valuation
Enterprise Value
3.34M
P/E (Trailing)
‪-0.43‬
P/E (Forward)
‪-0.70‬
PEG Ratio
‪-0.70‬
Price / Sales (TTM)
‪38.84‬
Price / Book
‪1.00‬
EV / EBITDA
‪-1.24‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪-6,238.81%‬
Return on Assets
‪-23.59%‬
Return on Equity
‪-122.28%‬
Ownership
Shares Outstanding
119.31M
Float
97.06M
Held by Insiders
‪9.99%‬
Held by Institutions
‪1.02%‬
Price stats
Beta
‪1.99‬
50-Day Avg
‪0.0416‬
200-Day Avg
‪0.0476‬
Dividends
Payout Ratio
‪0.00%‬
Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Peers - ADXN - Addex Therapeutics Ltd
Peer Comparison
Compared with companies in Biotechnology listed on SIX.
- ADXNSIXAddex Therapeutics Ltd6.28MMarket Cap-38.65%52-week change-0.67P/E (Trailing)‪0.00%‬Profit Margin
- BIONSIXBB Biotech AG3.06BMarket Cap+42.25%52-week change2.26P/E (Trailing)‪127.31%‬Profit Margin
- BSLNSIXBasilea Pharmaceutica Ltd800.76MMarket Cap+28.27%52-week change20.57P/E (Trailing)‪21.17%‬Profit Margin
- BIOVSIXBioVersys AG145.03MMarket Cap-1.20%52-week change-6.43P/E (Trailing)‪-386.62%‬Profit Margin
Profile Summary - ADXN - Addex Therapeutics Ltd
About
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company headquartered in Geneva, Switzerland, specializing in the development of novel small molecule allosteric modulators for neurological disorders. These orally available drugs target receptors to offer potential therapeutic advantages over conventional…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
